Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

Share Price is delayed by 15 minutes
Get Live Data
32.00    -0.75 (-2.29%)
Bid:
31.00
Ask:
33.00
Spread: 2.00 (6.452%)
Market Cap: £57.87m
IKA Live PriceLast checked at - London Stock Exchange

Intraday Ilika Plc Share Chart

AGM Statement

30 Sep 2015 07:00

RNS Number : 6113A
Ilika plc
30 September 2015
 

 

Ilika plc

("Ilika" or the "Company")

 

AGM Statement

 

Ilika (AIM: IKA), the accelerated materials innovation company, will hold its Annual General Meeting today at 2pm at the offices of Eversheds LLP, One Wood Street, London, EC2V 7WS.

 

Ahead of the formal proceedings Graeme Purdy, CEO of Ilika, will provide the following update to shareholders:

 

Since the announcement of our final results in July, operations at Ilika have been dominated by the activities associated with the production of our solid-state batteries. In March 2015 we announced commencement of solid-state battery production, which enabled us to enter into a dialogue with our OEM partners on integration of the batteries with their products. The principal applications being addressed are wireless sensors for smart buildings, transport and medical devices. These interactions resulted in a set of performance targets being defined for each application. The performance targets have been translated into a development roadmap with intermediate milestones to be achieved along the way. The technical team has been working hard to achieve these milestones over the summer period and solid progress is being made towards commercialisation.

 

Ilika's portfolio of patents, covering its solid-state battery technology, has also made good progress. We reported in March that we had received a Notice of Allowance in the United States for one of the applications and an Intention to Grant in Europe for another. Both were jointly filed with Toyota. As expected, these patents went to formal grant in those jurisdictions in June and July respectively. Earlier this week, Ilika announced that it had also received notification of grant of one of these patents in China. In July, a further three patent applications covering other aspects of our battery technology were published. We expect further filings to result from the development work currently being undertaken.

 

In August we reported that the European Patent Office had upheld Ilika's opposition to a fuel cell catalyst patent from a US national lab. Ilika invests significant sums in creating intellectual property to underpin the company's licensing model. Potentially competitive filings are monitored closely and are challenged where appropriate. The patent revocation means that Ilika now enjoys freedom to operate the European patent covering our palladium-alloy based fuel cell catalyst. While the adoption rate of fuel cell technology has always been difficult to predict, the recent launch of vehicles like the Toyota Mirai signals an increased focus by OEM's on cost-reduction in readiness for the mass market. Ilika's patented fuel cell catalyst materials are currently under evaluation by global car manufacturers and Tier 1 suppliers.

 

Also of note has been Ilika's recent success in attracting funding to support its work in developing advanced aerospace alloys. Last week, we announced that Ilika had been awarded a £466,000 grant to support its role leading a £2.15 million, 3-year collaborative project with Reliance, the University of Sheffield, GKN and BAE Systems. The project will develop a new generation of self-healing alloys for additive manufacturing (AM) processes. Forecasts for the AM market (also known as 3D printing) fall into the $230 bn- $550 bn range by 2025 and developing suitable alloys for this process will be a valuable enabling technology.

 

This AGM will also be a time of board renewal, with the retirement of Jack Boyer OBE after 11 years in the role and his replacement, pending shareholder confirmation, by Mike Inglis. Jack has overseen the growth of the company from a University spin-out in 2004, through three rounds of venture finance and a successful IPO in 2010. Mike brings a wealth of IP commercialisation experience to the board, from his time as Commercial Director at ARM Holdings. Mike's appointment builds on the addition of Professor Keith Jackson to the board in October 2014. This development of the board is part of a broader transition for Ilika from a project-based organisation to one with a greater product focus and we'd like to thank our shareholders for their continued support and enthusiasm during this period.

 

 

 

For more information contact:

 

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Tel: 023 8011 1400

Steve Boydell, Finance Director

 

 

 

Numis Securities Limited

Tel: 020 7260 1000

Oliver Cardigan/ Adrian Trimmings /

 

James Black

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 / ilika@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMPKCDQPBKDQCB
Date   Source Headline
21st May 20267:00 amRNSIlika Trading Update and Notice of Results
10th Apr 20264:01 pmRNSCollaboration with Brompton Bicycles
18th Mar 20267:00 amRNSPositive Feedback on Safety of Goliath Cells
10th Mar 20267:00 amRNSFirst Commercial Delivery to Cirtec Medical
24th Feb 202610:21 amRNSAward of Share Options
19th Feb 20267:00 amRNS-RIlika at Yellowstone Investor Evening: Replacement
22nd Jan 20267:00 amRNSHalf-year Financial Report
21st Jan 20267:00 amRNSIlika Secures Stereax Electrode Order from Cirtec
18th Dec 20257:00 amRNSInitial Stereax M300 Shipments
11th Dec 20257:00 amRNSIlika Ships 10Ah Goliath Battery Prototypes
20th Nov 20257:00 amRNSTrading Update & Notice of Half-Year Results
21st Oct 20257:00 amRNSCommissioning Complete for Goliath Pilot Line
1st Oct 202512:00 pmRNSExercise of Options and Total Voting Rights
23rd Sep 20253:43 pmRNSResult of AGM & Award of Executive Share Options
22nd Sep 20257:00 amRNSStart of Primed Solid-State Battery Programme
28th Aug 20257:00 amRNSNotice of AGM and Posting of Annual Report
18th Aug 20257:00 amRNSStereax Battery Milestone at Cirtec Medical
17th Jul 20258:56 amRNSHolding(s) in Company
17th Jul 20257:00 amRNSFinal Results
15th Jul 20257:00 amRNSAward of Government Grant Funding
11th Jun 20252:09 pmRNSNotice of Results
4th Jun 20252:14 pmRNSHolding(s) in Company
3rd Jun 20251:57 pmRNSHolding(s) in Company
28th May 20256:00 pmRNSResult of Oversubscribed Retail Offer
22nd May 20252:16 pmRNSRetail Offer for up to £0.5 million
22nd May 20251:53 pmRNSResult of Placing & Director Subscription
21st May 20255:14 pmRNSProposed Capital Raise
7th May 202510:03 amRNS-RIlika announces 2025 Investor Day
1st May 20257:00 amRNSGoliath P1 Cells Validated by Customer Testing
15th Apr 20257:00 amRNSGoliath Battery Achieves Scale-up Milestone
6th Mar 20257:00 amRNSGoliath Development Progress
27th Feb 20257:00 amRNSAward & Exercise of Share Options
6th Feb 20253:49 pmRNSHolding(s) in Company
5th Feb 20257:00 amRNSGoliath Scale-up Progress
21st Jan 20257:00 amRNSHalf-year Results
9th Jan 20257:00 amRNSStereax Equipment Commissioning Completed
19th Dec 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker
22nd Nov 20242:18 pmRNSAIM Rule 17 Schedule 2(g) Update
20th Nov 20247:00 amRNSGoliath D6 milestone reached
15th Nov 20247:00 amRNSTrading Update & Notice of Half-Year Results
10th Oct 20241:49 pmRNSHolding(s) in Company
3rd Oct 20247:00 amRNSFurther Goliath Technical Milestone Achieved
29th Aug 20247:00 amRNSPosting of Annual Report and Notice of AGM
11th Jul 20247:00 amRNSFinal Results
2nd Jul 20247:00 amRNSKey Technology Validation Milestone
1st Jul 20247:00 amRNSNominated Adviser and Joint Broker
31st May 20242:29 pmRNSHolding(s) in Company
29th May 202411:52 amRNSResults of General Meeting Open Offer and TVR
22nd May 20247:00 amRNSKey Goliath Technology Validation Milestone
16th May 20247:00 amRNSTrading Update, Notice of Results & Presentations

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.